{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:17:00Z","timestamp":1738041420756,"version":"3.33.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,26]]},"DOI":"10.7759\/cureus.78032","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:12:16Z","timestamp":1737958336000},"source":"Crossref","is-referenced-by-count":0,"title":["Familial Hypercholesterolemia: A Comprehensive Review of Advances in Treatment Strategies and the Role of Patient Beliefs"],"prefix":"10.7759","author":[{"given":"Hadi A","family":"Bakour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumana","family":"Hussain Timraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra Wadi","family":"Bin Saddiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nourah A","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husna","family":"Irfan Thalib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Alyarimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraheem","family":"Ali Algarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.07.006","article-title":"Familial hypercholesterolemia: advances in recognition and therapy","volume":"59","author":"Cartier JL","year":"2016","unstructured":"Cartier JL, Goldberg AC. Familial hypercholesterolemia: advances in recognition and therapy. Prog Cardiovasc Dis. 2016, 59:125-34. 10.1016\/j.pcad.2016.07.006","journal-title":"Prog Cardiovasc Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2019.09.014","article-title":"Corrigendum to \"Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender\" [Nutr Metab Cardiovasc Dis 29 (2019) 1068-1076]","volume":"29","author":"Mattina A","year":"2019","unstructured":"Mattina A, Giammanco A, Giral P, et al.. Corrigendum to \"Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender\" [Nutr Metab Cardiovasc Dis 29 (2019) 1068-1076]. Nutr Metab Cardiovasc Dis. 2019, 29:1431. 10.1016\/j.numecd.2019.09.014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5551\/jat.43372","article-title":"Novel approaches for the treatment of familial hypercholesterolemia: current status and future challenges","volume":"25","author":"Jiang L","year":"2018","unstructured":"Jiang L, Wang LY, Cheng XS. Novel approaches for the treatment of familial hypercholesterolemia: current status and future challenges. J Atheroscler Thromb. 2018, 25:665-73. 10.5551\/jat.43372","journal-title":"J Atheroscler Thromb"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-011-0219-9","article-title":"Familial hypercholesterolemia: present and future management","volume":"13","author":"Sjouke B","year":"2011","unstructured":"Sjouke B, Kusters DM, Kastelein JJ, Hovingh GK. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep. 2011, 13:527-36. 10.1007\/s11886-011-0219-9","journal-title":"Curr Cardiol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6515\/acs20160611a","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar S","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016, 32:631-9. 10.6515\/acs20160611a","journal-title":"Acta Cardiol Sin"},{"key":"ref6","article-title":"Simvastatin","year":"2021","unstructured":"Simvastatin. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney, Bethesda, MD; 2021."},{"key":"ref7","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","unstructured":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344:1383-9.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20160033","article-title":"Ezetimibe: clinical and scientific meaning of the IMPROVE-IT Study","volume":"106","author":"Correia LC","year":"2016","unstructured":"Correia LC. Ezetimibe: clinical and scientific meaning of the IMPROVE-IT Study. Arq Bras Cardiol. 2016, 106:247-9. 10.5935\/abc.20160033","journal-title":"Arq Bras Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.195906","article-title":"Proprotein convertase subtilisin\/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia","volume":"7","author":"Mazhar F","year":"2016","unstructured":"Mazhar F, Haider N. Proprotein convertase subtilisin\/kexin type 9 enzyme inhibitors: an emerging new therapeutic option for the treatment of dyslipidemia. J Pharmacol Pharmacother. 2016, 7:190-3. 10.4103\/0976-500X.195906","journal-title":"J Pharmacol Pharmacother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020323","article-title":"Inclisiran-safety and effectiveness of small interfering RNA in inhibition of PCSK-9","volume":"15","author":"Wo\u0142owiec \u0141","year":"2023","unstructured":"Wo\u0142owiec \u0141, Osiak J, Wo\u0142owiec A, et al.. Inclisiran-safety and effectiveness of small interfering RNA in inhibition of PCSK-9. Pharmaceutics. 2023, 15:10.3390\/pharmaceutics15020323","journal-title":"Pharmaceutics"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.699597","article-title":"The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases","volume":"9","author":"Abdelnour SA","year":"2021","unstructured":"Abdelnour SA, Xie L, Hassanin AA, Zuo E, Lu Y. The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases. Front Cell Dev Biol. 2021, 9:699597. 10.3389\/fcell.2021.699597","journal-title":"Front Cell Dev Biol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition With evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report","volume":"41","author":"Reeskamp LF","year":"2021","unstructured":"Reeskamp LF, Millar JS, Wu L, et al.. ANGPTL3 inhibition With evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report. Arterioscler Thromb Vasc Biol. 2021, 41:1753-9. 10.1161\/ATVBAHA.120.315204","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10050755","article-title":"The use of coenzyme Q10 in cardiovascular diseases","volume":"10","author":"Rabanal-Ruiz Y","year":"2021","unstructured":"Rabanal-Ruiz Y, Llanos-Gonz\u00e1lez E, Alcain FJ. The use of coenzyme Q10 in cardiovascular diseases. Antioxidants (Basel). 2021, 10:10.3390\/antiox10050755","journal-title":"Antioxidants (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.883251","article-title":"Effectiveness of coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Tsai IC","year":"2022","unstructured":"Tsai IC, Hsu CW, Chang CH, Tseng PT, Chang KV. Effectiveness of coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022, 13:883251. 10.3389\/fphar.2022.883251","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X14666180416115428","article-title":"Coenzyme Q10 in cardiovascular and metabolic diseases: current state of the problem","volume":"14","author":"Zozina VI","year":"2018","unstructured":"Zozina VI, Covantev S, Goroshko OA, Krasnykh LM, Kukes VG. Coenzyme Q10 in cardiovascular and metabolic diseases: current state of the problem. Curr Cardiol Rev. 2018, 14:164-74. 10.2174\/1573403X14666180416115428","journal-title":"Curr Cardiol Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2016-0149","article-title":"Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia","volume":"28","author":"T\u00f3th \u0160","year":"2017","unstructured":"T\u00f3th \u0160, \u0160ajty M, Pek\u00e1rov\u00e1 T, et al.. Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia. J Basic Clin Physiol Pharmacol. 2017, 28:327-36. 10.1515\/jbcpp-2016-0149","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11091698","article-title":"Coenzyme Q10 supplementation in statin treated patients: a double-blinded randomized placebo-controlled trial","volume":"11","author":"Dohlmann TL","year":"2022","unstructured":"Dohlmann TL, Kuhlman AB, Morville T, et al.. Coenzyme Q10 supplementation in statin treated patients: a double-blinded randomized placebo-controlled trial. Antioxidants (Basel). 2022, 11:10.3390\/antiox11091698","journal-title":"Antioxidants (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/nu14204383","article-title":"Combined supplementation of coenzyme Q(10) and other nutrients in specific medical conditions","volume":"14","author":"Tippairote T","year":"2022","unstructured":"Tippairote T, Bj\u00f8rklund G, Gasmi A, Semenova Y, Peana M, Chirumbolo S, Hangan T. Combined supplementation of coenzyme Q(10) and other nutrients in specific medical conditions. Nutrients. 2022, 14:10.3390\/nu14204383","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03659","article-title":"Synergistic anti-atherosclerotic role of combined treatment of omega-3 and co-enzyme Q10 in hypercholesterolemia-induced obese rats","volume":"6","author":"Ibrahim Fouad G","year":"2020","unstructured":"Ibrahim Fouad G. Synergistic anti-atherosclerotic role of combined treatment of omega-3 and co-enzyme Q10 in hypercholesterolemia-induced obese rats. Heliyon. 2020, 6:e03659. 10.1016\/j.heliyon.2020.e03659","journal-title":"Heliyon"},{"key":"ref21","article-title":"Familial hypercholesterolemia","author":"Levenson AE","year":"2000","unstructured":"Levenson AE, de Ferranti SD. Familial hypercholesterolemia. Endotext [Internet]. Feingold KR, Anawalt B, Blackman et al. MR, et al. (ed): MDText.com, Inc., South Dartmouth (MA); 2000."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00293-4","article-title":"The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review","volume":"19","author":"Fiorillo A","year":"2020","unstructured":"Fiorillo A, Barlati S, Bellomo A, et al.. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020, 19:43. 10.1186\/s12991-020-00293-4","journal-title":"Ann Gen Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030332","article-title":"Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare","volume":"16","author":"Marques L","year":"2024","unstructured":"Marques L, Costa B, Pereira M, et al.. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024, 16:10.3390\/pharmaceutics16030332","journal-title":"Pharmaceutics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2016.08.001","article-title":"The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction","volume":"181","author":"Rerup SA","year":"2016","unstructured":"Rerup SA, Bang LE, Mogensen UM, et al.. The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. Am Heart J. 2016, 181:35-42. 10.1016\/j.ahj.2016.08.001","journal-title":"Am Heart J"},{"key":"ref25","article-title":"Familial hypercholesterolemia","volume":"14","author":"Pejic RN","year":"2014","unstructured":"Pejic RN. Familial hypercholesterolemia. Ochsner J. 2014, 14:669-72.","journal-title":"Ochsner J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2015.1059354","article-title":"Personalized medicine: four perspectives of tailored medicine","volume":"7","author":"Ruberg SJ","year":"2015","unstructured":"Ruberg SJ, Shen L. Personalized medicine: four perspectives of tailored medicine. Stat Biopharm Res. 2015, 7:214-29. 10.1080\/19466315.2015.1059354","journal-title":"Stat Biopharm Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-69","article-title":"A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with familial hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial","volume":"10","author":"Broekhuizen K","year":"2010","unstructured":"Broekhuizen K, van Poppel MN, Koppes LL, Brug J, van Mechelen W. A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with familial hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial. BMC Public Health. 2010, 10:69. 10.1186\/1471-2458-10-69","journal-title":"BMC Public Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-348","article-title":"Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with familial hypercholesterolemia?","volume":"12","author":"Broekhuizen K","year":"2012","unstructured":"Broekhuizen K, Jelsma JG, van Poppel MN, Koppes LL, Brug J, van Mechelen W. Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with familial hypercholesterolemia?. BMC Public Health. 2012, 12:348. 10.1186\/1471-2458-12-348","journal-title":"BMC Public Health"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030290","article-title":"Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis","volume":"9","author":"Kinnear FJ","year":"2019","unstructured":"Kinnear FJ, Wainwright E, Perry R, et al.. Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis. BMJ Open. 2019, 9:e030290. 10.1136\/bmjopen-2019-030290","journal-title":"BMJ Open"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks D","year":"2003","unstructured":"Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003, 168:1-14. 10.1016\/S0021-9150(02)00330-1","journal-title":"Atherosclerosis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/J.LEARNINSTRUC.2010.02.004","article-title":"Dealing with conflicting or consistent medical information on the Web: when expert information breeds laypersons' doubts about experts","volume":"21","author":"Kienhues D","year":"2011","unstructured":"Kienhues D, Stadtler M, Bromme R. Dealing with conflicting or consistent medical information on the Web: when expert information breeds laypersons' doubts about experts. Learn Instr. 2011, 21:193-204. 10.1016\/J.LEARNINSTRUC.2010.02.004","journal-title":"Learn Instr"},{"key":"ref32","article-title":"Understanding middle students\u2019 beliefs about knowledge and learning using a multidimensional paradigm","volume":"94","author":"Schommer-Aikins M","year":"2000","unstructured":"Schommer-Aikins M, Mau W-C, Brookhart S, Hutter R. Understanding middle students\u2019 beliefs about knowledge and learning using a multidimensional paradigm. J Educ Res. 2000, 94:120-7.","journal-title":"J Educ Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1348\/000709904X22683","article-title":"Epistemological beliefs and approaches to learning: their change through secondary school and their influence on academic performance","volume":"75","author":"Cano F","year":"2005","unstructured":"Cano F. Epistemological beliefs and approaches to learning: their change through secondary school and their influence on academic performance. Br J Educ Psychol. 2005, 75:203-21. 10.1348\/000709904X22683","journal-title":"Br J Educ Psychol"},{"key":"ref34","article-title":"Epistemologische \u00dcberzeugungen und Fachverst\u00e4ndnis im Mathematik- und Physikunterricht","author":"K\u00f6ller O","year":"2000","unstructured":"K\u00f6ller O, Baumert J, Neubrand J. Epistemologische \u00dcberzeugungen und Fachverst\u00e4ndnis im Mathematik- und Physikunterricht. Mathematische und physikalische Kompetenzen am Ende der gymnasialen Oberstufe . Baumert J, Bos W, Lehmann R (ed): TIMSS\/III. Dritte Internationale Mathematik- und Naturwissenschaftsstudie\u2014Mathematische und naturwissenschaftliche Bildung am Ende der Schullaufbahn, 2000. 229-69."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg AC","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al.. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011, 5:S1-8. 10.1016\/j.jacl.2011.04.003","journal-title":"J Clin Lipidol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/JCN.0000000000000896","article-title":"Evaluation of the effectiveness of individually tailored lifestyle intervention in patients with familial hypercholesterolemia","volume":"37","author":"Beyece \u0130ncazli S","year":"2022","unstructured":"Beyece \u0130ncazli S, \u00d6zer S, Kayik\u00e7io\u011flu M. Evaluation of the effectiveness of individually tailored lifestyle intervention in patients with familial hypercholesterolemia. J Cardiovasc Nurs. 2022, 37:465-74. 10.1097\/JCN.0000000000000896","journal-title":"J Cardiovasc Nurs"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-15-8","article-title":"Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial","volume":"15","author":"P\u00e1rraga-Mart\u00ednez I","year":"2015","unstructured":"P\u00e1rraga-Mart\u00ednez I, Rabanales-Sotos J, Lago-Deibe F, et al.. Effectiveness of a combined strategy to improve therapeutic compliance and degree of control among patients with hypercholesterolaemia: a randomised clinical trial. BMC Cardiovasc Disord. 2015, 15:8. 10.1186\/1471-2261-15-8","journal-title":"BMC Cardiovasc Disord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-019-4869-4","article-title":"The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH)","volume":"20","author":"Kinnear FJ","year":"2020","unstructured":"Kinnear FJ, Wainwright E, Bourne JE, Lithander FE, Hamilton-Shield J, Searle A. The development of a theory informed behaviour change intervention to improve adherence to dietary and physical activity treatment guidelines in individuals with familial hypercholesterolaemia (FH). BMC Health Ser Res. 2020, 20:27. 10.1186\/s12913-019-4869-4","journal-title":"BMC Health Ser Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2019.06.006","article-title":"Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: a protocol","volume":"16","author":"Jones LK","year":"2020","unstructured":"Jones LK, Gidding SS, Seaton TL, et al.. Developing implementation strategies to improve uptake of guideline-recommended treatments for individuals with familial hypercholesterolemia: a protocol. Res Soc Admin Pharm. 2020, 16:390-5. 10.1016\/j.sapharm.2019.06.006","journal-title":"Res Soc Admin Pharm"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101198","article-title":"IMPACT-FH Study for implementing innovative family communication and\u00a0cascade testing strategies for familial hypercholesterolemia","volume":"3","author":"Jones LK","year":"2024","unstructured":"Jones LK, Campbell-Salome G, Walters NL, et al.. IMPACT-FH Study for implementing innovative family communication and\u00a0cascade testing strategies for familial hypercholesterolemia. JACC Adv. 2024, 3:101198. 10.1016\/j.jacadv.2024.101198","journal-title":"JACC Adv"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040035","article-title":"Patient and provider perspectives on a decision aid for familial hypercholesterolemia","volume":"8","author":"Farwati M","year":"2018","unstructured":"Farwati M, Kumbamu A, Kochan DC, Kullo IJ. Patient and provider perspectives on a decision aid for familial hypercholesterolemia. J Pers Med. 2018, 8:10.3390\/jpm8040035","journal-title":"J Pers Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S266249","article-title":"Familial hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents","volume":"17","author":"Tada H","year":"2021","unstructured":"Tada H, Takamura M, Kawashiri MA. Familial hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021, 17:59-67. 10.2147\/VHRM.S266249","journal-title":"Vasc Health Risk Manag"},{"key":"ref43","article-title":"Pharmacogenetics: implementing personalized medicine","volume":"6","author":"Mini E","year":"2009","unstructured":"Mini E, Nobili S. Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab. 2009, 6:17-24.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000732","article-title":"The genetic counselor's role in management of patients with dyslipidemia","volume":"32","author":"Brown EE","year":"2021","unstructured":"Brown EE. The genetic counselor's role in management of patients with dyslipidemia. Curr Opin Lipidol. 2021, 32:83-8. 10.1097\/MOL.0000000000000732","journal-title":"Curr Opin Lipidol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12884","article-title":"Precision medicine, AI, and the future of personalized health care","volume":"14","author":"Johnson KB","year":"2021","unstructured":"Johnson KB, Wei WQ, Weeraratne D, et al.. Precision medicine, AI, and the future of personalized health care. Clin Transl Sci. 2021, 14:86-93. 10.1111\/cts.12884","journal-title":"Clin Transl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334652-familial-hypercholesterolemia-a-comprehensive-review-of-advances-in-treatment-strategies-and-the-role-of-patient-beliefs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T06:12:18Z","timestamp":1737958338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334652-familial-hypercholesterolemia-a-comprehensive-review-of-advances-in-treatment-strategies-and-the-role-of-patient-beliefs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.78032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}